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ABSTRACT
Introduction. Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic renal disorder. It leads to 
multiple extra-renal complications, with intracranial aneurysms (IA) among the most serious. Biological markers could become 
tools in identifying patients at risk of an IA. MicroRNAs 16 (miR-16) and 25 (miR-25) have been proposed as being markers of IAs 
in the general population. In the current study, we attempted to discover if they may also be considered markers of IAs in ADPKD.
Material and methods. 64 renal transplant recipients with ADPKD were included. After magnetic resonance angiography of 
the brain, they were divided into a case group (IA+, n = 13) and a control group (IA-, n = 51). Expression of miRNAs in plasma 
was analysed by qRT-PCR.
Results. The expression of miR-16 was higher in the control (IA-) group. There was no statistically significant difference between 
the groups in terms of miR-25 expression.
Conclusions and clinical implications. MicroRNA-16 is a potential marker of IAs in renal transplant recipients with ADPKD. It may 
become a tool to identify patients who should undergo screening for an IA. 
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) 
is the most common genetic renal disorder. Apart from end-
stage kidney disease (ESKD) in a large proportion of patients, 
it leads to multiple extra-renal complications; subarachnoid 
haemorrhages due to the rupture of an intracranial aneurysm 
(IA) are among the most serious [1]. In fact, the prevalence of 
intracranial aneurysms in ADPKD patients is approximately 
five times greater than in the general population, amounting 
to 10-11.5% [2, 3], and may be further increased in special 
subpopulations e.g. renal transplant recipients with AD-
PKD [4]. Despite the fact that universal screening for IAs in 
ADPKD populations has been proposed [5, 6], it is still not 
widely accepted [1, 7]. Therefore, there is a need to improve 
the selection of patients who should undergo screening to 
enable the detection of the maximum number of IAs in the 
pre-symptomatic period. Biological markers could become 
tools to identify patients at risk of an IA.
MicroRNAs (miRNAs) are short molecules of RNA 
(18–25 nucleotides in length). They are involved in post-tran-
scriptional regulation of gene expression. They are present in 
plasma, and are relatively resistant to enzymatic degradation. 
Due to the unique patterns of change in different diseases, 
miRNAs are considered to be disease-specific biomarkers. 
MicroRNAs 16 (miR-16) and 25 (miR-25) have been proposed 
as being markers of IAs in the general population [8]. In the 
current study, we attempted to discover if they may also be 
considered markers of IAs in ADPKD.
Material and methods
Our work was a sub-study of a cross-sectional study on the 
prevalence of IAs in renal transplant recipients with ADPKD; 
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its design and results have already been reported [9]. Partici-
pants in that study who consented to also participate in this 
sub-study were included. Participants were renal transplant 
recipients with ADPKD managed at the outpatient department 
of the Department of Immunology, Transplant Medicine and 
Internal Diseases of the Medical University of Warsaw, Poland. 
The inclusion criteria were: a diagnosis of ADPKD, being 
a renal transplant recipient, age 18-plus, lack of contraindica-
tions for magnetic resonance imaging, and written informed 
consent. Sixty-four patients met the inclusion criteria and were 
enrolled. In all patients, a 3D time-of-flight magnetic resonance 
angiography (MRA) of the brain was performed. All imaging 
studies were performed between January 2015 and November 
2019 using an Ingenia 1.5T HP (Philips Healthcare, Best, the 
Netherlands) scanner, and in total 20 ml of blood was collected 
for further examination. Peripheral venous blood was collected 
into EDTA-containing tubes. Whole blood was first centrifuged 
at 1,600g for 10 minutes, and then the supernatant was trans-
ferred into a fresh tube and centrifuged again at 13,000g for 
10 minutes. The clear plasma was aliquoted and stored at -80°C 
until use. All procedures were carried out on ice. 
Then, according to the design of a case-control study, the 
patients were divided into two groups according to the pres-
ence or absence of IA.
Expression of miRNA-16 and miRNA-25 was analysed 
by qRT-PCR. A column method miRNeasy Serum/Plasma 
advanced kit (Quiagen) was used for RNA isolation from previ-
ously frozen plasma samples according to the manufacturer’s 
instructions. RNA quality and quantity were determined spec-
trophotometrically with a NanoDrop ND-2000 (NanoDrop 
Technologies, Inc.). A Quiagen Spike-In control C.elegans 
miR39 miRNA mimic was used as an internal control for 
miRNA expression. Specific TaqMan Gene Expression assays 
were purchased from Applied Biosystems. A TaqMan Mi-
croRNA reverse transcription kit and Universal Master Mix II 
(Applied Biosystems) were used for RNA reverse transcription 
and real-time PCR amplification. RT-PCR was performed on 
an ABI Prism 7500 Sequence Detection System (Applied Bio-
systems) using specific TaqMan primers and probes (Applied 
Biosystems): hsa-miR-16 (UAGCAGCACGUAAAUAUUG-
GCG) and hsa-miR-25 (AGGCGGAGACUGGGCAAUUG). 
U6 was used as a housekeeping gene. Each sample was analysed 
in triplicate. The relative gene expression was calculated by the 
2−ΔΔCt method. The results were presented as a fold change 
of gene expression in patients with an intracranial aneurysm 
and in those without, where the reference point was expression 
in the non-aneurysmal group. 
Normality of data distribution was measured with a Kol-
mogorov-Smirnov test. Statistical analysis was performed by 
comparing ΔCt values using nonparametric tests for inde-
pendent samples (Mann-Whitney U test). All analyses were 
performed with Statistica software version 12.5 (StatSoft, 
Tulsa, OK, USA). A P value of < .05 was considered statisti-
cally significant.
This study was conducted in accordance with the principles 
of the Declaration of Helsinki, and the ethics committee of the 
Medical University of Warsaw approved the protocol. All pa-
tients gave written informed consent for inclusion in the study.
Results
64 patients were included in the study, comprising 
33 (52%) men and 31 (48%) women. All included patients 
were white and all were recipients of their first renal transplant. 
The characteristics of the study group are set out in Table 1. 
Among this study group, IA was detected in 13 cases, while 
51 patients were IA-free.
The expression of miR-25 was found in all patients, and 
the expression of miR-16 was found in all but one patient; that 
case was excluded from analysis. We observed statistically 
significant differences in the expression of miR-16 between 
patients with and without IA, based on the accepted level of 
significance p < 0.05 and Z statistic of the Mann-Whitney 
U test (Z = 2.90616) with continuity correction p = 0.01658 as 
well as based on accurate U statistics (743). The expression 
of miR-16 was higher in the control (non-aneurysmal) 
group, and the ratio of mean miR-16 expression level was 
1.00:0.39 (control:cases). A similar relationship was also ob-
served for miR-25, although the results did not reach statistical 
significance (Z = -0.1441; U = 1,126.5; p = 0.88866).
Discussion
The prevalence of IAs in renal transplant recipients with 
ADPKD has been assessed as being between 14.9% [4] and 
22.7% [9]. Developing biomarkers may shed light on the 
Table 1. Characteristics of study group
Characteristic Value
Whole group (n = 64) IA (+) group (n = 13) IA (-) group (n = 51)
Men/women (n, %) 33/31 52%/48% 6/7 46%/54% 27/24 53%/47%
Median age, years (range, IQR) 60.7 (38–78, 11.1) 55.7 (37.5–67.2, 8.7) 62.1 (39.5–78.2, 10.5)
Median time after transplant in months (range, IQR) 35.6 (1–236, 77.9) 8.9 (1.2 – 100, 49.7) 46 (0.6–236.2, 72.1)
Median eGFR [CKD-EPI formula], ml/min/1.73m2 (range, IQR) 45.6 (7–97.3, 32.3) 38.9 (22.4–82.6, 22.5) 47.7 (7–97.3, 34.5)
IQR — interquartile range, eGFR — estimated glomerular fraction rate, IA — intracranial aneurysm
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pathogenesis of IAs in this group. Additionally, biomarkers 
may become tools useful in the selection of patients who 
should undergo imaging for an IA. 
miR-16 belongs to the most abundant miRNAs present 
in human plasma. Because its level was considered to be 
relatively stable, it was previously used as the housekeeping 
gene in qPCR assays. However, it was later shown that the 
plasma levels of miR-16 can change in certain diseases. Ac-
cording to the study by Li et al. [8], expression of miR-16, 
together with miR-25, is increased in patients with IA 
compared to healthy controls. miR-16 is expressed by 
vascular endothelial cells and is involved in angiogenesis 
[8]. While the function of endothelial cells is disturbed 
in ADPKD [10], it seemed desirable to verify the results of 
Li et al. [8] in ADPKD patients. 
Our results show that, indeed, plasma expression of miR-
16 is altered in ADPKD patients after renal transplantation 
with IA, but, in contrast to the results of Li et al. [8], we ob-
served decreased expression. Additionally, we did not observe 
altered plasma levels of miR-25 in this particular group of 
patients. Therefore, according to our results, miR-16, but not 
miR-25, could become a potential biomarker of IAs in ADPKD 
patients after renal transplantation.
Our results suggest that the pathogenesis of IAs in ADPKD 
may be different compared to IAs in the general population. 
That may explain numerous differences in the clinical picture 
of IAs between ADPKD patients and the general population, 
namely their prevalence, age at development, lack of gender 
differences etc. [2]. Thus, there is a need to take into account 
the distinct clinical proceedings with these particular cases. 
For instance, clinical biomarkers of IAs, if developed for 
the general population, may not be applicable to ADPKD 
patients, at least after kidney transplantation. Additionally, 
it would be of interest to compare levels of miR-16 in renal 
transplant recipients to those in the general population. This 
could potentially explain the differences between our results 
and those of Li et al. [8].
The fact that the plasma levels of miR-16 may change 
in certain diseases could also impact upon our results. For 
example, blood levels of miR-16 can change during vascular 
rejection of a renal graft [11]. In all of our patients, the 
graft function was stable at the moment of sample collec-
tion; however, our results should be interpreted cautiously 
due to the fact that some confounding factors might be 
omitted in the analysis. Therefore, further studies on this 
subject are needed.
Some limitations of our study should be noted. Firstly, 
due to the characteristics of the Polish population, only 
Caucasians were included in our study; results in other popu-
lations may differ. Secondly, the group was relatively small, 
and our observations should be confirmed in a larger study 
including populations of different ethnicities. Thirdly, only 
renal graft recipients were included in this study, and addi-
tional factors connected to this fact (e.g. immunosuppressive 
treatment, asymptomatic infections) might lead to bias. 
Additionally, renal graft recipients are in general older than 
patients in the pre-ESKD period, and therefore our results 
may not reflect the situation in the entire ADPKD population.
The clinical utility of miR-16 as a biomarker of IA in renal 
transplant recipients with ADPKD, and, possibly, in the whole 
ADPKD population, requires verification in further studies.
Conclusions and clinical implications
MicroRNA-16 is a potential marker of IA in renal trans-
plant recipients with ADPKD. It may become a tool to identify 
patients who should undergo screening for IAs. 
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